The Gliknik Board of Directors has deep industry expertise with a track record for discovering and developing marketed drugs and generating successful exits for investors.
David S. Block – Chairman
See Our Founders page.
Paul A. Friedman, M.D. – Non-executive Director
Dr. Friedman was formerly the Chief Executive Officer of Incyte Corporation. Under Dr. Friedman’s leadership, Incyte developed and launched Jakafi® (ruxolitinib), an FDA-approved drug for patients with intermediate or high-risk myelofibrosis. From 1994 to 1998, Dr. Friedman served as President of R & D for the DuPont Merck Pharmaceutical Company and from 1998 to 2001 as the President of DuPont Pharmaceuticals Research Laboratories, a wholly owned subsidiary of the DuPont Company. From 1991 to 1994, he served as Senior Vice President at Merck Research Laboratories. In these positions, Dr. Friedman has overseen the discovery and development of numerous drugs and brought Sustiva® (efavirenz) to market. Prior to his work at Merck and DuPont, Dr. Friedman was an associate professor of medicine and pharmacology at Harvard Medical School. Dr. Friedman is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He received his A.B. in biology from Princeton University and his M.D. from Harvard Medical School. Dr. Friedman is also a director of Incyte, Auxilium, Synta, Durata Therapeutics, and VeraStem.
Skip Klein – Non-executive Director
Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. Mr. Klein currently serves as a Board Director of the public biotechnology company Isis Pharmaceuticals, Inc. as well as of the Prospector Funds, Inc., an SEC-registered investment company that manages two no-load mutual funds. He has previously served on the boards and Audit Committees of BioMarin Pharmaceutical, Inc.; Clinical Data, Inc.; Genaissance Pharmaceuticals, Inc.; Guilford Pharmaceuticals, Inc.; NPS Pharmaceuticals, Inc.; OSI Pharmaceuticals, Inc.; PDL BioPharma, Inc.; Savient Pharmaceuticals, Inc.; and Synbiotics, Inc. Mr. Klein also serves on the boards of private and non-profit entities. From 1989 to 1998, Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. He has previously served as a Venture Partner of Red Abbey Venture Partners, L.P. and of MPM Capital. Mr. Klein received a B.A., summa cum laude, in Economics from Yale University, and an MBA from the Graduate School of Business at Stanford University.
Mark D. Lerner – Non-executive Director
Mark D. Lerner is a Partner in Chesapeake Partners, a firm that he co-founded in 1991 to achieve above-average returns through “event specific” investing with a value overlay. Mr. Lerner has extensive investment banking experience analyzing, acquiring and managing a wide variety of businesses. He brings his valuation expertise to Chesapeake Partners research efforts and his operational experience to the management of the firm. Previously, Mr. Lerner worked with Resource Holdings Capital Group, a firm that invested and managed a leveraged buyout fund. Prior to that, Mr. Lerner participated in the acquisition and management of businesses, worked in the mergers and acquisitions group at Merrill Lynch Capital Markets, and was a credit analyst at the J. Henry Schroder Bank and Trust Co. Mr. Lerner earned a B.A. from the College of the University of Pennsylvania and a B.S. in Economics from the Wharton School of the University of Pennsylvania. He is a Director on the Boards of Teach for America: Baltimore and Hope Elephants, a member of The Undergraduate Executive Board of the Wharton School of the University of Pennsylvania, a Distinguished Advisor to the Association of Universities for Research in Astronomy and an appointed member of the Mayor of Baltimore’s Pay for Success Work Group. He served as the Chairman of a capital campaign that raised in excess of $16 million for The Park School of Baltimore, and completed a three year term as President of its Board of Trustees. Mr. Lerner and his wife, Traci, have four children. Mr. Lerner is currently leading an effort to improve the education and healthcare of children in Baltimore City.
Richard S. Levy, M.D. – Non-executive Director
Dr. Richard S. Levy is currently Executive Vice President, Chief Drug Development and Medical Officer at Incyte Corporation. In this position he has been responsible for the clinical development and registration of Jakafi® as well as an expanding clinical development portfolio in Oncology and Inflammation. Dr. Levy has more than 20 years of experience in the pharmaceutical and biotechnology sectors through his prior positions at Celgene, DuPont Pharmaceuticals and Novartis. Dr. Levy has extensive clinical research, regulatory and product development skills and has worked in multiple therapeutic areas. Prior to joining Incyte in 2003, Dr. Levy served as Vice President, Biologic Therapies at Celgene. From 1997 to 2002, he was with DuPont Pharmaceuticals first as Vice President of Regulatory Affairs and Pharmacovigilence and then as Vice President, Medical and Commercial Strategy. In these positions, he played an important role in the development, registration, approval and commercialization of Sustiva®, a leading anti-HIV drug. He was at Novartis from 1991 to 1997 in positions of increasing responsibility in clinical research and regulatory affairs. Dr. Levy received his B.A. from Brown University, his M.D. from the University of Pennsylvania School of Medicine, and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in Gastroenterology and Hepatology at UCLA.
Raymond F. Schinazi, Ph.D., D.Sc. (Hon.) – Non-executive Director
Dr. Schinazi is the Frances Winship Walters Professor of Pediatrics and Director of the Laboratory of Biochemical Pharmacology at Emory University. He serves as Senior Research Career Scientist at the Atlanta Department of Veterans Affairs and Director of the Scientific Working Group on Viral Eradication for the NIH-sponsored Emory University Center for AIDS Research (CFAR). Dr. Schinazi received his B.Sc. (1972) and Ph.D. (1976) in chemistry from the University of Bath, England. He has authored over 500 peer-reviewed papers and seven books and holds 92 issued U.S. patents and over 120 non-U.S. national stage patents and patent applications, which have resulted in 12 New Drug Applications (NDA). A world leader in nucleoside chemistry, Dr. Schinazi is best known for his pioneering work on HIV and HCV drugs d4T (stavudine), 3TC (lamivudine), FTC (emtricitabine/Emtriva), LdT (telbivudine), and most recently sofosbuvir (Sovaldi), which are now approved by the FDA. He is also the founder of five biotechnology companies including Pharmasset, Inc. (VRUS; acquired by Gilead in 2012 for $11.4 B) and Idenix Pharmaceuticals (IDIX; sold to Merck for $3.85 Bn in 2014). More than 94% of HIV-infected individuals in the U.S. on combination therapy take at least one of the drugs he invented, and it is estimated that his work has saved more than 3 million lives worldwide. His contributions related to HCV are expected to have a profound positive impact on the approximately 170 million people worldwide suffering from chronic infection. Dr. Schinazi served on the Presidential Commission on AIDS and is the recipient of numerous awards including the 2006 Distinguished Scientist Award from the Hepatitis B Foundation, the Friends of the National Library of Medicine 2013 Distinguished Medical Science Award, and the SCRIP “100 Leaders” Award in 2014. He was also chosen in 2011 as one of Emory University’s “175 History Makers.” He currently serves as a Governing Trustee for the Foundation for AIDS Research (amfAR). He was inducted into the Technology Hall of Fame of Georgia in March 2012, received the Intellectual Property Legends Award in October 2012, and was inducted into the National Academy of Inventors as a Charter Fellow in January 2013.